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Abstract
Background: The Human Papillomavirus (HPV) genome is divided into early and late coding sequences, including
8 open reading frames (ORFs) and a regulatory region (LCR). Viral gene expression may be regulated through
epigenetic mechanisms, including cytosine methylation at CpG dinucleotides. We have analyzed the distribution of
CpG sites and CpG islands/clusters (CGI) among 92 different HPV genomes grouped in function of their preferential
tropism: cutaneous or mucosal. We calculated the proportion of CpG sites (PCS) for each ORF and calculated the
expected CpG values for each viral type.
Results: CpGs are underrepresented in viral genomes. We found a positive correlation between CpG observed and
expected values, with mucosal high-risk (HR) virus types showing the smallest O/E ratios. The ranges of the PCS
were similar for most genomic regions except E4, where the majority of CpGs are found within islands/clusters. At
least one CGI belongs to each E2/E4 region. We found positive correlations between PCS for each viral ORF when
compared with the others, except for the LCR against four ORFs and E6 against three other ORFs. The distribution
of CpG islands/clusters among HPV groups is heterogeneous and mucosal HR-HPV types exhibit both lower
number and shorter island sizes compared to cutaneous and mucosal Low-risk (LR) HPVs (all of them significantly
different).
Conclusions: There is a difference between viral and cellular CpG underrepresentation. There are significant
correlations between complete genome PCS and a lack of correlations between several genomic region pairs,
especially those involving LCR and E6. L2 and L1 ORF behavior is opposite to that of oncogenes E6 and E7. The
first pair possesses relatively low numbers of CpG sites clustered in CGIs while the oncogenes possess a relatively
high number of CpG sites not associated to CGIs. In all HPVs, E2/E4 is the only region with at least one CGI and
shows a higher content of CpG sites in every HPV type with an identified E4. The mucosal HR-HPVs show either
the shortest CGI size, followed by the mucosal LR-HPVs and lastly by the cutaneous viral subgroup, and a trend to
the lowest CGI number, followed by the cutaneous viral subgroup and lastly by the mucosal LR-HPVs.
Background
Human papillomavirus (HPV) constitute a group of over
100 different types. HPV infect stratified epithelia, both
mucosal and cutaneous and associate with benign and
malignant proliferative disorders. Viral types that prefer-
entially infect mucosal epithelia are grouped into either
a low-risk group (LR-HPV) not associated with cancer,
or into a high-risk group (HR-HPV) whose members are
found in almost all cases of cervical cancer [1]. HPV are
non-lytic, non-enveloped, icosahedral-shaped viruses
with a circular, double-stranded DNA genome of
approximately 8.0 kb that is functionally divided into
two coding regions (denoted E for early or L for late)
and one regulatory region or LCR. The E region
includes six major open-reading frames (ORFs) encod-
ing functional proteins (E1, E2 and E4) and oncopro-
teins (E5, E6 and E7), and the L region encodes the two
capsid proteins, L1 and L2. E4 is expressed in both early
and late stages of the viral life cycle [2].
HPV gene expression is mainly regulated at the tran-
scriptional and post-transcriptional levels and several
studies have suggested that viral DNA methylation may
* Correspondence: sgalvan@unam.mx
1Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de
México, México
Full list of author information is available at the end of the article
Galván et al. BMC Genomics 2011, 12:580
http://www.biomedcentral.com/1471-2164/12/580
© 2011 Galván et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.be associated with viral gene expression and cancer pro-
gression [3-6].
Most of the work on HPV methylation has been car-
ried out on the two main viral types involved in cervical
cancer (types 16 and 18). In both genomes there is a
progressive increase in methylation from asymptomatic
carriers, through benign lesions and pre-malignant dis-
ease, to cancer tumors. Nevertheless, there is heteroge-
neity of CpG methylation in viral genomes derived from
clinical specimens [4-7], and the exact role of viral DNA
methylation remains unclear.
Furthermore, based on Epstein-Barr virus studies it
has been proposed that viral genome methylation may
enable a proportion of infected cells to survive cytotoxic
T-cell immune surveillance [8,9], and studies on adeno-
virus late viral genes suggest that they are more sensitive
to methylation than early ones [10]. In the case of HPV
L2 and L1 genes, they have been proposed to be prefer-
entially recognized by the cellular methylation machin-
ery [11,12].
Methylation is the only known covalent modification
of DNA in eukaryotes and plays an important regulatory
role in vertebrates by silencing specific genes during
development and cell differentiation. Cytosine methyla-
tion occurs at the 5’-position of the pyrimidine ring,
mainly within a CpG context (m5CpG), although
methylation of cytosines in different contexts has
recently been described [13,14] and 5-hydroxymethylcy-
tosine (5 hmC), a novel DNA modification was reported
[15].
Usually, the presence of m5CpG in genomic DNA is
associated with chromatin condensation and inactivation of
gene expression. Nevertheless, it is not clear whether the
primary evolutionary role of DNA methylation is transcrip-
tional silencing or a host defense system against endogen-
o u so re x o g e n o u sp a r a s i t i cs e q u e n c ee l e m e n t s[ 1 6 ] .
In the genomes of higher eukaryotes, CpG dinucleo-
tides are usually underrepresented, from one third down
to 5% of their expected frequency [17-20]. The mechan-
ism proposed to explain this underrepresentation, first
recognized in prokaryotic systems [21], is that CpG sites
are mutagenic due to the frequent conversion of methyl-
cytosines to thymines through deamination [22].
Similar to their hosts, CpG dinucleotides are underre-
presented in the majority of small DNA viruses, although
to a lesser extent [23]. It has been proposed that low
CpG frequencies may either allow viruses to avoid
methylation by host methyltransferases and thus maxi-
mize their transcriptional efficiency, or could be a means
of reducing CpG mediated immune responses [24].
The general view is that CpG sites in vertebrates,
grouped within clusters or islands (CGI), are mostly
unmethylated in promoter regions of transcriptionally
active genes, and methylated in promoter regions of
transcriptionally inactive genes. In contrast, methylation
in body genes seems to be evolutionarily conserved and
plays an important role in tissue- or cell-specific alterna-
tive promoter regulation. Furthermore, tumor cells
usually show hypomethylation of the majority of the
genome and methylation of CGIs in promoter regions
of tumor suppressor genes [14,25].
According to Gardiner-Garden and Frommer [26] a
CGI is defined as a DNA fragment of at least 200 bp
containing at least 50% of CpG’s, with a CpG Observed/
Expected (O/E) ratio of 0.60 or higher and at least a 100
bp gap in between different CGIs. This definition,
despite its popularity, has raised many criticisms and
various different proposals have been postulated [27-31].
Han et al., [32] recently compared three computational
algorithms for CpG island identification and, based on
vertebrate gene function and other genomic factors, the
Takai and Jones criteria performance was the best. The
analysis of 132 CGIs across the entire human chromo-
some 21 allowed researchers to identify several attri-
butes associated with either methylation-resistance or
methylation-sensitivity of CGIs [33].
The majority of the proposals for CGI identification
and criteria to analyze methylation predisposition at
CpG islands cannot be directly applied to HPV genomes
because of their small size. In addition, lack of multiple
promoter regions and the scarce data on methylation of
different viral types make this scenario difficult.
Because in our view, understanding DNA methylation
may benefit from our knowledge of CpG distribution
along different viral genomes, we have analyzed genomic
and regional proportions of CpG sites (PCS) and their
arrangement into CGIs, in most human papillomavirus
types sequenced to date. To our knowledge, there has
been no comprehensive analysis of CGIs in virus gen-
omes. We propose hypotheses about their functional
roles, considering HPVs as both a single group or as
subgroups in function of their preferential tropism
(cutaneous and mucosal) and their associated risk to
induce cancer (mucosal low- and high-risk).
Results
CpG sites are underrepresented among HPV genomes,
although to a lesser extent than in their hosts
After identifying all CpG sites among 92 available HPV
DNA sequences, we calculated the expected CpG value
for each viral genome. The expected number of CpG
sites was calculated as the number of ‘C’s multiplied by
the number of ‘G’s in the viral genome, divided by the
genome size.
When we compared the CpG observed vs. the
expected values for each viral type, a significant differ-
ence was clear (one side p = 0, Chi square test). In addi-
tion, a positive correlation was found (two sided p =
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indicating a similar proportion of CpGs diminishing
irrespective of viral type. As anticipated, CpG sites are
underrepresented in viral genomes, although to a lesser
extent than in their human host genome [17,20]. The
average difference between means is 50.5% (ranging
from 32.5% to 58.1%).
Interestingly, most HR-HPV infecting mucosal epithe-
lia show CpG O/E ratios below the O/E average ratio
(0.50); only five HR-HPV types (18, 26, 45, 39, and 68)
show differences slightly above the average ratio (addi-
tional file 1, Table S1). In fact, the HR-HPVs possess
the lowest average (0.47) CpG O/E ratio which means
that this viral sub-group shows a deeper CpG underre-
presentation. CpG O/E average ratios for LR-and cuta-
neous HPV types are 0.49 and 0.51, respectively.
In Figure 1, we can observe CpG values as a function
of the expected values for all 92 sequenced HPV gen-
omes. The calculated O/E ratio for each individual
nucleotide among different viral genomes indicates that
C (0.8) and G (0.9) are underrepresented while A (1.2)
and T (1.1) are overrepresented within HPV genomes.
HPV E4 is the region with the highest proportion of CpGs
We calculated each PCS as the number of CpG sites
divided by the total number of nucleotides in the con-
sidered sequence. Then we plotted PCS for each viral
region in ascending order (Figure 2) independently of
the viral type. This means that each x axis value may
represent more than one viral type.
From Figure 2 (and additional file 2, Table S2, where all
analyzed viral genomes are listed), it is clear the E4 ORF
possesses the highest regional PCS value (61 out of 68
HPV types where this region has been identified; see
Methods section for HPV types lacking reported ORFs),
and that the E2 region (where E4 is co-located) does not
show similar PCS values (average E2 PCS without HPV
types lacking E4 was 0.028). In three out of 68 viral types,
E7 exhibits the highest PCS values while the LCR region
shows the highest PCS values in four out of 68 types.
Regional average PCS (and range) for individual ORFs
and the LCR are as follows: E6, 0.024 (0.002 to 0.045);
E7, 0.030 (0.010 to 0.054); E1, 0.018 (0.009 to 0.035); E2,
0.029 (0.014 to 0.050); E4, 0.051 (0.025 to 0.088); L2,
0.023 (0.011 to 0.043); L1, 0.018 (0.009 to 0.036); and
LCR, 0.027 (0.009 to 0.054).
When HPVs are grouped in function of their preferen-
tial tropism, the E4 ORF PCS averages are the highest
when compared to any other region. In fact, E4 ORF
PCS averages are quite close, irrespective of type: for
cutaneous, 0.054 and for mu c o s a l ,0 . 0 4 9 ,s i m i l a rt o
when mucosal HPVs were grouped in function of risk:
low risk, 0.050 and high risk, 0.048. Furthermore, E4
average PCS values are around twice the highest average
PCS from any other region in each viral group/subgroup
(data not shown).
Interestingly, O/E ratios for A (1.16) and G (0.96)
individual nucleotides in the E4 ORF, follow the same
Figure 1 Relationship between CpG observed and expected
values for HPV genomes.
Figure 2 Distribution of HPV types in function of regional PCS
values. Every data set is graphed according to the order of each
particular regional PCS, from the lowest to the maximum. PCS is the
number of CpG sites divided by the total number of nucleotides in
the regional sequence.
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(0.68) seems underrepresented and C (1.20) overrepre-
sented, compared to whole genome values. When Arc-
sin transformed O/E ratios for single nucleotides in E4
and in the whole genome were compared, we found that
the two sets of data are significantly different (p =
4.94E-14; t test), even though they are significantly cor-
related (p = 006; Pearson Product Moment Correlation).
PCS were Arc-sin transformed in order to properly use
statistical procedures, as mentioned in the Methods
section.
HPV type distributions in function of regional proportion
of CpG sites are dissimilar
HPV types were ordered in function of regional Arc-sin
transformed PCS (AsPCS) and compared to each other
using a Pearson linear correlation coefficient and two
sided t tests. Results are shown in Table 1, where it can
be seen that 36 out of 45 are significant correlations.
This means that any viral type closely maintains its rela-
tive position in function of each significant correlated
couple of regional PCS. There is a lack of correlation
between LCR PCS and those from the E1, E4, L2 and
L1 regions, as well as the average of the ORFs; between
E6 PCS and those from the E7, E2 and E4 regions; and
between E7 PCS and that from the L2 region.
The distribution of CpG islands/clusters among HPVs is
heterogeneous
CGI location is summarized in Table 2 (and described
in additional file 3, Table S3). There are in average 3
CGIs per HPV genome (ranging from 1 to 8) and the
average island size is 394 bp, ranging from 203 to 1379
bp. Twenty two HPV types possess a single CGI with a
average size of 447 bp (ranging from 210 to 835); 25
types possess two CGIs with a average size of 360 bp
(ranging from 215 to 562); 15 types possess three CGIs
with a average size of 303 bp (ranging from 234 to 426);
10 types possess four CGIs, average size of 365 bp (ran-
ging from 241 to 510); 6 types possess five CGIs,
average size of 481 bp (ranging from 265 to 724); 6
types possess six CGIs, average size of 477 bp (ranging
from 391 to 575); 7 types possess seven CGIs, average
size of 381 bp (ranging from 344 to 424), and just one
type (HPV 57) possesses eight CGIs with an average size
of 505 bp (ranging from 209 to 1159). None of the
viruses lack CGIs, and in all cases at least one CGI
belongs to the E2/E4 region.
HPV E2/E4 is the region with the highest number of CGIs
We found that the viral region with the highest number
of CGIs (CGIn) is E2/E4; each viral type possessing at
least one CGI in this region. It is important to make
clear that in the case of E4, as in any other region, we
have only taken into account those HPV types where
this ORF has been identified. Other regions which most
commonly contain CGIs include the E1, E7 and L2
ORFs which have CGIs in at least half of HPV types;
the L1 ORF and LCR regions with one CGI in 25 to
50% of viral types, and finally, the region where less
than 25% of the viral types possess one CGI is E6.
In most types, there is not an exact correspondence
between whole genome CGIn and regional CGIn
Table 1 p values for correlations* between regional AsPCS values
Genomic Regions All ORFs E6 E7 E1 E2 E4 L2 L1 LCR
HPV genome 0.0000 0.0006 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0016
All ORFs 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.2493
E6 0.9080 0.0000 0.2674 0.2453 0.0000 0.0000 0.0000
E7 0.0112 0.0015 0.0293 0.0965 0.0019 0.0286
E1 0.0000 0.0001 0.0000 0.0000 0.9719
E2 0.0000 0.0000 0.0059 0.0000
E4 0.0036 0.0003 0.0564
L2 0.0000 0.7086
L1 0.1081
*Pearson Product Moment Correlation and two sided t test.
Table 2 Proportion of CpG islands per HPV for each viral
group
CGIs E6 E7 E1 E2 E4 L2 L1 LCR HPV
Genome
High-Risk
HPVs
0.07 0.47 0.33 1.00 1.00 0.13 0.00 0.00 1.60
Low-Risk
HPVs
0.32 0.55 1.14 1.03 1.00 1.00 0.55 0.46 3.93
Mucosal
HPVs
0.22 0.51 0.83 1.02 1.00 0.66 0.34 0.28 3.04
Cutaneous
HPVs
0.16 0.49 0.84 1.00 1.00 0.58 0.44 0.39 3.02
All HPVs 0.19 0.50 0.84 1.01 1.00 0.62 0.39 0.33 3.03
Maximum
number
11221342 8
Minimum
number
00011000 1
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than one viral region, it is taken into account in every
comprehended region; even if there is just one CGI in
the whole genome. This applies particularly to the E2
and E4 regions because the E4 ORF is located within
the E2 ORF, although in a different reading frame (see
Table 2).
High-risk HPV types exhibit lesser and shorter CpG
islands/clusters
When grouped by tropism, CGI average sizes and
ranges are as follows: cutaneous HPV types averaging
446 bp (from 203 to 1211 bp); all mucosal HPV types,
345 bp (from 205 to 1379 bp); mucosal LR-HPV types,
363 bp (from 205 to 1379 bp), and mucosal HR-HPV
types, 275 bp (from 210 to 410 bp). Notably, when CGI
frequencies per size were compared, we found signifi-
cant differences between cutaneous and mucosal HPVs
(p < 0.0005) as well as between mucosal LR- and HR-
HPVs (p < 0.0001, Chi square test). Additionally, both
cutaneous and mucosal viral types share an average of
3.0 CGIs per viral genome (ranging from 1 to 8), and
among mucosal types, LR-HPVs show an average of
3.93 CGIs per viral genome in contrast to HR-HPVs
that show only 1.60 CGIs. When compared frequencies
per number of CGI, we also found significant differences
between cutaneous and mucosal HPVs (p < 0.005) as
well as between mucosal LR- and HR-HPVs (p < 0.001,
Chi square test).
Thirty out of 45 cutaneous and 32 out of 47 mucosal
types possess 3 or less CGIs, and 15 out of 45 cutaneous
and 15 out of 47 mucosal types possess more than 3
CGIs. In the mucosal group, 14 out of 29 LR- and all 18
HR-HPVs possess 3 or less CGIs, and 15 out of 29 LR-
HPVs posses more than 3 CGIs (additional file 3, Table
S3).
Although CGIs seem regionally distributed in a similar
manner between cutaneous and mucosal types (except
for E6, L1 and LCR), there is a notable difference
between the proportion of CGIs among both mucosal
HR- and LR-types (see Table 2), especially for regions
E6 (0.07 and 0.32, respectively), E1 (0.33 and 1.14,
respectively), L2 (0.13 and 1.00, respectively), L1 (0.0
and 0.55, respectively), andL C R( 0 . 0a n d0 . 4 6 ,r e s p e c -
tively). In fact, among mucosal HR-HPV types, only
HPV 33 contains a CGI in the E6 region; only HPV 45
contains a couple of CGIs in the L2 region, and none of
the mucosal HR-HPVs contain CGIs in either the L1 or
LCR regions.
Interestingly, when focusing only on regions where
islands were identified (excluding any region with no
CGI; see Table S3), the regionp o s s e s s i n gt h eh i g h e s t
CGI number is L1 (average 1.71 CGIs on 21 HPV
types), followed by L2 (average 1.58 CGIs on 36 HPV
types), E1 (average 1.26 CGIs on 61 HPV types) and
LCR (average 1.20 CGIs on 25 HPV types). Oncogenes
E6 and E7 as well as E2 and E4 ORFs share 1 CGI on
17, 45, 92 and 68 HPV types, respectively.
Discussion
To our knowledge, this is the first systematic analysis of
CGIs, as well as of CpG site distribution performed in
92 HPV types. This analysis provides the main structure
underlying the methylation phenomenon, guiding the
identification of interesting genomic regions for future
epigenetic experimental studies.
As anticipated [23], we found significant differences
between CpG observed and expected values among all
sequenced HPV genomes. Nevertheless, contrary to the
notorious underrepresentation of CpG sites among
eukaryotic genomes where they account for only one
third down to 5% of the expected values; viral genomes
have an underrepresentation of only around 50% of the
expected CpG values. According to the co-evolution
hypothesis, it would be expected that both human and
HPV genomes exhibit similar CpG underrepresentation
values. The great differences found could be related to
other relevant phenomena, such as the species-specific
codon usage and the genomic base composition. In fact
a relationship between codon use and base composition
with C+G content in HPVs was previously found
[34,35].
In this context, it seems necessary to mention that
HPVs are small sized viral DNA genomes that do not
evolve rapidly, in contrast to other viruses. It has been
calculated that approximately 200,000 years are needed
for 17 bp to change in these genomes [36].
In a biological context, a significant correlation
between CpG observed and expected values could
reflect global common functional constrictions shared
by most HPV types. At the same time, the AsPCS inter-
regional lack of correlations point to local functional
constriction divergences, particularly in the E6 and LCR
regions (Table 2). Nevertheless, more studies of different
HPV types are necessary to confirm it.
Interestingly, L2 and L1 ORFs show a parallel CpG
behavior. Both of them possess relatively low PCS
arranged mostly in CGI. The L2 region is sixth place in
average PCS value and fourth place in island number,
and L1 is eighth place in average PCS value and sixth
p l a c ei ni s l a n dn u m b e r .I ti sk n o w nt h a ti nl o wg r a d e
cervical lesions associated to HPV 16, the viral genome
is episomal, hypomethylated, and the L1 and L2 ORFs
are expressed in order to generate viral capsids. In con-
trast, most high grade cervical lesions show viral DNA
integrated, hypermethylated, and the L1 and L2 ORFs
are not expressed. In vertebrates, methylation in body
genes plays an important role in tissue- or cell-specific
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are used for alternative promoter identification [37].
Even though this is a risky idea, it is tempting to specu-
late that viral capsid coding ORFs behave similarly and
that when the cell hypermethylates them, it is possible
that the L1/L2 region plays a role as an alternative pro-
moter for viral genes and, when integrated, for some
cellular genes.
Additionally, viral oncogenes also show a parallel CpG
behavior, but in an opposite manner as the capsid cod-
ing genes. Both of them possess relatively high PCS
values associated to few CGI. E7 occupies the second
place according to average regional PCS values and the
fifth place according to the average island number,
while the E6 region occupies the fifth place according to
regional PCS and the eighth place according to the aver-
age island number. This means CpG sites are widely dis-
tributed and suggest both regions could be sensitive to
methylation, especially when the HPVs integrate in to
the cell genome.
The E4 ORF seems to be a special case because of its
multiple roles during the viral cycle. It is involved in
diverse cell and viral functions, especially in diminishing
keratinocyte integrity [38], cell cycle arrest at G2 [39],
HPV DNA replication [40] and expression of late pro-
teins [41], possibly through several proteolysis products
from the E4 protein [42]. In fact, the E4 ORF is
expressed throughout the viral cycle [2]. Its functions
and continuous expression could impound hard func-
tional restrictions to sequence mutations, as well as the
need for a mechanism involved in avoiding methylation.
The maintenance of CpG sites in CGIs could be a kind
of compromise to meet sequence code restrictions with
the necessary expression of the E4 protein.
In addition to the underrepresentation of CpG sites in
HPV genomes, single nucleotide proportions point to T
and A increased frequencies at the expense of G and C
frequencies, reinforcing the C ® T mutation hypothesis
as a result of CpG deamination.
Nevertheless, the E4 region does not share the same
behavior. Amazingly, even when A and G proportions
are similar to those from the whole genome, C frequen-
cies seem to be increased at the expense of Ts. This
f a c t ,a d d e dt ot h eh i g hn u m b e ro fC p Gs i t e s ,m o s t l y
arranged into CGIs, leads to the question of whether
there is any mechanism to avoid C ® Tm u t a t i o n s ,
resulting from deamination, that affects the HPV and
specially the viral E4 region. In fact, there exist repair
enzymes that remove deaminated bases; specifically, thy-
mine DNA glycosylase (TDG) and methyl-CpG binding
domain protein 4 (MBD4) which are able to remove
either uracil or thymine from G·U and G·T miss-pair-
ings where follow-on base excision repair enzymes
restore a G·C pair [43,44].
When grouped by tropism, the cutaneous HPV group,
shows the greatest CGI average size (446 bp), followed
by the LR-HPV group with an intermediate CGI average
size (363 bp) and the HR-HPV group shows the smallest
average CGI size (272 bp). Additionally, even though
CGIn from both cutaneous and mucosal HPV types
share similar values (3 CGIs, average), it seems there is
a trend toward smaller CGIn in HR- compared to LR-
HPVs (1.6 and 3.93, respectively). These data raise ques-
tions about the possible role of CGIs on the interaction
between virus and cells. At the same time, this suggests
a possible differential susceptibility to methylation in
function of either HPV tropism or associated risk.
Nevertheless, the only experimental studies on methy-
lomes have been carried out on HPV types 16 and 18,
where methylation changes and high heterogeneity were
observed along the viral infection phases [3-8]. In sum-
mary, those inter-group differences could be related to
different viral infection epigenetic strategies.
Finally, it should be interesting to examine virus tar-
geted genes in the human genome and see what their
CGI and CpG features are. We hope that our analysis of
CpG and CGI distribution among HPV genomes can
provide elements for rational experimental approaches
related to biological and evolutionary processes of these
viruses and their hosts.
Conclusions
First, we want to point out that this work is based solely
on sequence feature analysis, so the results reported
here may need experimental corroboration. In this
study, we found that there are both significant differ-
ences and correlations between CpG observed and
expected values among all sequenced HPV genomes,
and that viral genomes have an underrepresentation of
only around 50% compared to eukaryotic genomes
where underrepresentation is from 30 down to 5%.
The regional analysis of CpG site distribution shows
that correlations between complete genome PCS are sig-
nificant, even though there is a lack of correlation
between several genomic region pairs, especially those
involving LCR and E6. Furthermore, we found that L2
and L1 ORFs exhibit an opposite behavior to oncogenes
E6 and E7; the first pair possessing relatively low num-
bers of CpG sites which are associated to CGI while the
oncogenes possess a relatively high number of CpG sites
which are not associated to CGI. We would point out
that E4 is the region possessing the highest content of
CpGs in every HPV type where an E4 is identified.
From the CGI analysis, the E2/E4 i st h eo n l yr e g i o n
with at least one CGI in every HPV, and the main dif-
ference between this region and the complete genome is
that in the E4 region the frequency of Cs seems
increased at the expense of Ts. The mucosal HR-HPVs
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Page 6 of 10possess the shortest CGI sizes, followed by the mucosal
LR-HPVs and finally by the cutaneous viral subgroup.
A tt h es a m et i m e ,t h em u c o s a lH R - H P V ss h o wat r e n d
toward lower CGI numbers, followed by the cutaneous
viral subgroup and finally by the mucosal LR-HPVs.
Finally, we hope that our analysis of CpG and CGI
distribution among HPV genomes can provide support
for rational experimental approaches related to the bio-
logical and evolutionary processes of these viruses and
their hosts.
Methods
Our CpG analysis comprises two phases: the first one is
the comparison of CpG site distribution among HPV
types as a single group, and in the second phase we
identify possible similarities or differences in CpG site
distribution associated to the preferential tropism and/
or the risk of cancer caused by the mucosal viral sub-
groups. The CpG distribution refers to CpG proportions
(PCS) and either CGI sizes or numbers.
Data Source
HPV DNA sequences were obtained online from Gen-
Bank (U.S. National Library of Medicine and National
Institutes of Health; see additional file 1, Table S1). The
main criterion for viral genome selection was that every
nucleotide sequence had been previously identified as an
HPV type by a taxonomic study. We selected all HPV
sequences included in the classification schemes from
De Villiers et al. [45], based on the L1 sequence, and
from Diallo et al. [46], based on complete genome
sequences.
Sequence from HPV type 16 includes the changes pro-
posed by the Theoretical Biology and Biophysics Group
in Los Alamos National Laboratory. All 92 HPV gen-
omes included in the analysis were reedited so that all
sequences begin at the first nucleotide from the E6
ORF. Exceptions to this are HPV types 14D and 71,
because neither has a reported E6 ORF. Additionally,
HPV types 14D and 3 lack reported E7 ORFs, HPV type
53 lacks a reported E1 ORF and 24 viral types lack
reported E4 O R F s( H P V1 a ,3 ,7 ,8 ,9 ,1 0 ,1 2 ,1 4 D ,1 5 ,
17, 19, 25, 26, 27, 30, 32, 34, 40, 45, 50, 52, 53, 56, and
71).
Because the absence of data may contribute to bias in
the analysis, putative ORFs for each HPV type lacking
reported ORFs were identified using the online tool
“ORF finder” [47]. The main criteria for putative ORF
selection was the size of the identified coding regions
and the existence of only one candidate ORF in each
considered region. We took into account single frag-
ments of 200 bp or greater, and then we calculated the
PCS for these putative ORFs. As can be seen in Addi-
tional File 4, Table S4, we found putative single E1a n d
E7 ORFs for HPV types 53 and 3, respectively. In the
case of HPV 14D, we found single E6a n dE7O R F s ,
however these were found to overlap by more than 100
bp. For HPV types without a reported E4 ORF, we iden-
tified a single putative ORF in only three viral types:
HPV 25, 26 and 32. The other 21 HPV types had more
than one identified ORF: we found 11 HPV types with
2, 8 HPV types with 3, 1 HPV type with 4 and 1 HPV
type with 5 putative E4 ORFs.
The PCS for the putative ORFs did not notably
change the regional PCS averages nor the analysis of the
results (See additional file 5, Table S5).
Finally, in order to avoid bias in the results, we
included one sequence from each HPV type and avoided
any variant type sequences.
Input Data
The input data comprehended the entire genome, each
ORF and LCR, including start and end sites, for every
HPV type.
We analyzed the entire genomes of 92 viral sequences,
as well as dividing them into 8 regions (E1, E2, E4, E6,
E7, L1,a n dL2 ORFs, and LCR). Because of the scarce
amount of data, we did not include three reported ORFs
into the analysis: the E8 ORF has been found only in
HPV 1; the E5 ORF is present in only 23 out of 92 HPV
types (5, 6a, 11, 13, 16, 18, 31, 33, 35, 39, 41, 42, 51, 58,
59, 67, 68, 69, 70, 74, 82 and 85), and the E5BO R Fi s
only reported for two HPV types (11 and 31).
Output Data
In order to identify the CpG sites we used PISMA, a
computational tool we designed, which is available upon
request to SCG and/or RAS. PISMA allows the location
and identification of motifs ranging between 2 to 10
bases, in up to 10 kb DNA sequences. In addition, this
tool will count the number of motifs in defined regions.
We have identified the individual CpG sites per region
from all HPV sequences, and based on those data from
PISMA, we calculated the PCS as the number of CpG
sites divided by total number of nucleotides in the
sequence. Identification of putative CpG islands/clusters
was carried out using CpG island Explorer 2.0, publi-
cally available in http://www.uscnorris.com/cpgislands2/
cpg.aspx[28]; parameters used in CpG island identifica-
tion were those from Gardiner-Garden and Frommer
[26]: CpG 50% or more, ObsCpG/ExpCpG ratio 0.60 or
higher, at least 200 bp size and 100 bp gap. In Figure 3
results obtained for HPV 16 are shown.
PCS Arc-sin transformations were calculated in order
to properly use parametric statistical procedures that are
not suitable for proportion data because of the binomial
nature of the biological process (CpG occurrence). In
summary, the distribution of proportions is often
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distribution more normal.
Finally, we calculated the CpG expected values for
each viral genome in order to compare them with the
CpG observed values.
Data Analysis
Possible relationships between data results were identi-
fied using rho Spearman Rank Correlation and Chi
square tests, as well as Pearson Product Moment Corre-
lation and two sided t tests. Calculations were carried
out using ad hoc Excel macros and corroboration of cal-
culations, using free online statistics software [48,49].
Revision Procedure
In order to check for possible mistakes in the calcula-
tions, we reviewed the whole procedure by randomly
selecting three groups of thirty HPV types each. One
group was used to repeat the input data procedures; a
second group was used to repeat the output data proce-
dures, and the third group was used to repeat statistical
and p value calculations.
Additional material
Additional file 1: Table S1. CpG observed and expected values for
each HPV type. The table contains the GenBank accession number, the
CpG observed and expected numbers, and the CpG O/E ratio, for all 92
HPV types included in the analysis.
Additional file 2: Table S2. Proportion of CpG sites among different
genomic regions. The table contains the proportion of CpGs in the E6,
E7, E1, E2, E4, L2 and L1 ORFs, and the LCR, the entire genome and all
ORFs together, for every viral type.
Additional file 3: Table S3. CpG islands per region from each HPV
type. The table contains the CpG island number in the E6, E7, E1, E2, E4,
L2 and L1 ORFs, and the LCR and of entire genome, the CGI average size
and the tropism for every viral type.
Additional file 4: Table S4. Putative ORFs from HPV types lacking
reported ORFs. The table contains every possible coding fragment 200
bp or larger for each HPV type lacking reported ORFs; the starting and
ending sites, and the corresponding PCS values.
Additional file 5: Table S5. p values for correlations between
regional AsPCS when putative ORFs are included. The table contains
p values for correlations between regional AsPCS values when AsPCS
from putative ORFs are included.
List of abbreviations
HPV: human papillomavirus; LR-HPV: low-risk HPV types; HR-HPV: high-risk
HPV types; ORF: open reading frame; PCS: proportion of CpG sites; AsPCS:
Arc-sin transformed proportion of CpG sites; m5CpG: methylated CpG site;
CGI: CpG island; CGIn: CpG island number; E(number): viral early protein; L
(number): viral late protein; E(number): viral early ORF; L(number): viral late
ORF; LCR: long control region; SRPK1: serine-arginine-rich protein kinase 1.
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